Scorr-Insert
X

Find Novel Drugs for Infections and Infectious Diseases under Discovery

A collaboration with SCORR Marketing

Loading...

All Data

Filters Filter refresh
×
FILTER DATA :
Country filter
    News Type filter
      Company filter
        Product Type filter
          Deal Size filter
            refresh

            Product Type Full Screen

            Companies Full Screen

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): Antibodies

            Therapeutic Area: Infections and Infectious Diseases

            Highest Development Status: Discovery Product Type: Large molecule

            Partner/Sponsor/Collaborator: Eli Lilly

            Deal Size: Undisclosed Upfront Cash: Undisclosed

            Deal Type: Collaboration May 22, 2020

            Details:

            AbCellera will use its world-leading antibody drug discovery platform in a multi-year collaboration to identify antibodies against up to nine targets.

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): Undisclosed

            Therapeutic Area: Infections and Infectious Diseases

            Highest Development Status: Discovery Product Type: Small molecule

            Partner/Sponsor/Collaborator: Undisclosed

            Deal Size: Undisclosed Upfront Cash: Undisclosed

            Deal Type: Partnership May 21, 2020

            Details:

            Atomwise democratizes access to its advanced AI technology with 15 research collaborations underway to enable academic researchers to discover novel therapies for this pandemic and those in the future.

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): Prophylactic recombinant protein vaccine

            Therapeutic Area: Infections and Infectious Diseases

            Highest Development Status: Discovery Product Type: Vaccine

            Partner/Sponsor/Collaborator: Not Applicable

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable May 18, 2020

            Details:

            In a project supported by the Japan Agency for Medical Research and Development (AMED), Shionogi and its subsidiary, UMN Pharma, are pursuing the discovery and development of a recombinant protein vaccine for COVID-19, using their unique technology.

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): Single domain antibodies

            Therapeutic Area: Infections and Infectious Diseases

            Highest Development Status: Discovery Product Type: Large molecule

            Partner/Sponsor/Collaborator: Not Applicable

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable May 18, 2020

            Details:

            Abcore has demonstrated these therapeutic candidates bind to the spike protein of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) and functionally block binding to the Angiotensin Converting Enzyme-2 (ACE2) receptor.

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): Monoclonal antibody

            Therapeutic Area: Infections and Infectious Diseases

            Highest Development Status: Discovery Product Type: Large molecule

            Partner/Sponsor/Collaborator: Vanderbilt University Medical Center

            Deal Size: Undisclosed Upfront Cash: Undisclosed

            Deal Type: Collaboration May 07, 2020

            Details:

            For assessment and future licensing and clinical development, certain monoclonal antibodies discovered in Dr. James Crowe's laboratory at the Vanderbilt Vaccine Center will be shared with IDBiologics.

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): IgM antibodies

            Therapeutic Area: Infections and Infectious Diseases

            Highest Development Status: Discovery Product Type: Large molecule

            Partner/Sponsor/Collaborator: BeiGene

            Deal Size: Undisclosed Upfront Cash: Undisclosed

            Deal Type: Collaboration April 29, 2020

            Details:

            The companies will leverage their combined technology in an effort to discover, develop, and manufacture novel IgM and IgA antibodies targeting SARS-CoV-2 for the potential treatment of COVID-19.

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): Antisense oligonucleotides

            Therapeutic Area: Infections and Infectious Diseases

            Highest Development Status: Discovery Product Type: Large molecule

            Partner/Sponsor/Collaborator: Guangzhou’s Sun Yat-sen University

            Deal Size: Undisclosed Upfront Cash: Undisclosed

            Deal Type: Collaboration April 28, 2020

            Details:

            Under this agreement, Secarna will employ its proprietary LNAplusTM platform to develop antisense oligonucleotides (ASOs) which specifically suppress the expression of a certain host factor that is essential for the viral infection cycle.

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): Monocloncal antibodies

            Therapeutic Area: Infections and Infectious Diseases

            Highest Development Status: Discovery Product Type: Large molecule

            Partner/Sponsor/Collaborator: State of North Dakota

            Deal Size: $0.1 million Upfront Cash: Undisclosed

            Deal Type: Funding April 24, 2020

            Details:

            The State of North Dakota has provided ImmunoPrecise grant for the development of a novel platform for the rapid development of COVID-19 drugs and other emerging pathogens.

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): Self-Assembling Vaccine

            Therapeutic Area: Infections and Infectious Diseases

            Highest Development Status: Discovery Product Type: Vaccine

            Partner/Sponsor/Collaborator: Not Applicable

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable April 24, 2020

            Details:

            Candidate selected to initiate testing of HaloVax™, a Self-Assembling Vaccine to protect people at risk of COVID-19 infection .

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): COVID-19 drug

            Therapeutic Area: Infections and Infectious Diseases

            Highest Development Status: Discovery Product Type: Undisclosed

            Partner/Sponsor/Collaborator: Not Applicable

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable April 22, 2020

            Details:

            The Joint venture will deploy Cyclica's unique AI platform to accelerate the development of new treatments based on Mannin's Tie2 based platform.

            PharmaCompass